See What HealthDay Can Do For You
Contact Us

Molecule May Correct Toxicity of Muscular Dystrophy Defect

Study finds that oligonucleotide disrupts toxic RNA-protein complexes in mice

FRIDAY, July 17 (HealthDay News) -- A synthetic molecule can correct the consequences of the genetic defect causing myotonic dystrophy in a mouse model of the disease, according to a study in the July 17 issue of Science.

Thurman M. Wheeler, M.D., and colleagues from the University of Rochester in New York examined whether CAG25, a morpholino antisense oligonucleotide, could target the toxic RNA of the gene responsible for myotonic dystrophy type 1 in a mouse model of the disease, releasing the MBNL1 protein that carries out an important cellular function.

The researchers found that CAG25 could disrupt these toxic RNA-protein complexes when injected into muscle, releasing MBNL1 and restoring its ability to perform its function. This led to a restoration of the function of a muscle-specific chloride channel and a marked reduction in myotonia.

"Taken together, these data supply proof of concept that agents inhibiting deleterious RNA-protein interactions have therapeutic potential in RNA-dominant disorders," Wheeler and colleagues conclude.

Abstract
Full Text (subscription or payment may be required)

Physician's Briefing

HealthDay

HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.